Ewing sarcoma family of tumors-derived small extracellular vesicle proteomics identify potential clinical biomarkers.
EWS-ETS
Ewing sarcoma
biomarkers
exosomes
extracellular vesicles
Journal
Oncotarget
ISSN: 1949-2553
Titre abrégé: Oncotarget
Pays: United States
ID NLM: 101532965
Informations de publication
Date de publication:
04 Aug 2020
04 Aug 2020
Historique:
received:
18
04
2020
accepted:
20
06
2020
entrez:
22
8
2020
pubmed:
22
8
2020
medline:
22
8
2020
Statut:
epublish
Résumé
Ewing Sarcoma Family of Tumors (ESFT), the second most common pediatric osseous malignancy, are characterized by the pathognomonic chromosomal We performed the first high quality proteomic study of ESFT-derived sEVs from 5 ESFT cell lines representing the most common From these analyses, two membrane bound proteins with biomarker potential were selected, CD99/MIC2 and NGFR, to develop a liquid-based assay enriching of ESFT-associated sEVs and detection of sEV mRNA cargo ( In this study, we demonstrate utilization of circulating ESFT-associated sEVs in pediatric patients as a source of minimally invasive diagnostic and potentially prognostic biomarkers.
Identifiants
pubmed: 32821345
doi: 10.18632/oncotarget.27678
pii: 27678
pmc: PMC7415402
doi:
Types de publication
Journal Article
Langues
eng
Pagination
2995-3012Subventions
Organisme : NIGMS NIH HHS
ID : P20 GM113226
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA168524
Pays : United States
Organisme : NIAAA NIH HHS
ID : P50 AA024337
Pays : United States
Organisme : NIGMS NIH HHS
ID : P20 GM103418
Pays : United States
Organisme : NIGMS NIH HHS
ID : P20 GM130423
Pays : United States
Organisme : NCI NIH HHS
ID : R33 CA214333
Pays : United States
Déclaration de conflit d'intérêts
CONFLICTS OF INTEREST Authors have no conflicts of interest to declare.
Références
Expert Rev Mol Diagn. 2019 Dec;19(12):1079-1088
pubmed: 31687863
Biochem Pharmacol. 2012 Jun 1;83(11):1484-94
pubmed: 22230477
Cell Mol Life Sci. 2018 Jan;75(1):1-19
pubmed: 29080091
Talanta. 2013 Feb 15;105:80-6
pubmed: 23597992
J Natl Compr Canc Netw. 2017 Feb;15(2):155-167
pubmed: 28188186
J Clin Oncol. 2000 Jan;18(1):4-11
pubmed: 10623687
Cancer Manag Res. 2018 Jan 09;10:49-60
pubmed: 29386915
Mol Cell Proteomics. 2002 Nov;1(11):845-67
pubmed: 12488461
BMC Cancer. 2012 Jan 17;12:22
pubmed: 22251860
Nat Rev Immunol. 2002 Aug;2(8):569-79
pubmed: 12154376
Nat Neurosci. 2002 Nov;5(11):1131-6
pubmed: 12404007
Transl Neurodegener. 2017 Feb 2;6:3
pubmed: 28184302
J Cancer Res Clin Oncol. 1987;113(2):187-91
pubmed: 3558454
Oncotarget. 2017 Sep 1;8(43):75742-75755
pubmed: 29088906
J Thromb Haemost. 2014 May;12(5):614-27
pubmed: 24618123
J Clin Oncol. 2005 Jul 1;23(19):4354-62
pubmed: 15781881
Cancer Genet. 2012 Jul-Aug;205(7-8):391-404
pubmed: 22868000
J Mol Diagn. 2018 Jan;20(1):63-77
pubmed: 29104083
Sci Rep. 2015 Jun 12;5:11295
pubmed: 26067326
Cancer Treat Rev. 2002 Oct;28(5):255-71
pubmed: 12435372
Adv Exp Med Biol. 2011;702:132-42
pubmed: 21713683
Semin Immunopathol. 2011 Sep;33(5):419-40
pubmed: 21174094
Semin Cancer Biol. 2003 Aug;13(4):275-81
pubmed: 14563122
N Engl J Med. 1994 Aug 4;331(5):294-9
pubmed: 8022439
Proc Natl Acad Sci U S A. 2011 Feb 8;108(6):2366-71
pubmed: 21262801
Med Pediatr Oncol. 2003 May;40(5):276-87
pubmed: 12652615
Crit Rev Oncog. 1996;7(1-2):89-100
pubmed: 9109499
N Engl J Med. 2003 Feb 20;348(8):694-701
pubmed: 12594313
Nat Med. 2015 Jul;21(7):827
pubmed: 26151329
Curr Protoc Cell Biol. 2006 Apr;Chapter 3:Unit 3.22
pubmed: 18228490
Biol Cell. 2013 Jul;105(7):289-303
pubmed: 23521563
Sarcoma. 2011;2011:856190
pubmed: 20981347
Br J Cancer. 2018 Aug;119(5):615-621
pubmed: 30131550
BMC Bioinformatics. 2009 May 27;10:161
pubmed: 19473525
J Mol Med (Berl). 2019 Jul;97(7):957-972
pubmed: 31025088
Cancer Res. 2009 Mar 1;69(5):1776-81
pubmed: 19208848
J Pediatr Hematol Oncol. 2008 Jun;30(6):425-30
pubmed: 18525458
JAMA Oncol. 2016 May 1;2(5):608-615
pubmed: 26822149
Eur J Cancer. 2008 Mar;44(5):699-709
pubmed: 18294840
J Clin Oncol. 2012 Nov 20;30(33):4148-54
pubmed: 23091096
Clin Exp Immunol. 2018 Jun;192(3):271-283
pubmed: 29431869
PLoS Genet. 2014 Jul 10;10(7):e1004475
pubmed: 25010205
Ann Oncol. 1998 Mar;9(3):275-81
pubmed: 9602261
Pediatr Hematol Oncol. 2012 Feb;29(1):1-11
pubmed: 22295994
Proc Natl Acad Sci U S A. 2014 Jan 14;111(2):711-6
pubmed: 24379393
Oncologist. 2006 May;11(5):503-19
pubmed: 16720851
Mol Cell Proteomics. 2018 Mar;17(3):495-515
pubmed: 29242380
Lab Chip. 2014 Oct 7;14(19):3773-80
pubmed: 25099143
Oncotarget. 2018 Apr 10;9(27):19006-19013
pubmed: 29721179
Nat Med. 2012 Jun;18(6):883-91
pubmed: 22635005
Int J Cancer. 2011 Mar 1;128(5):1139-50
pubmed: 20473914
Nat Methods. 2009 May;6(5):359-62
pubmed: 19377485
Nature. 2015 Jul 9;523(7559):177-82
pubmed: 26106858
Lab Chip. 2018 Dec 4;18(24):3790-3801
pubmed: 30474100
Hum Pathol. 2001 Sep;32(9):976-83
pubmed: 11567228
Transl Res. 2018 Nov;201:136-153
pubmed: 30031766
Ther Adv Med Oncol. 2018 Jun 01;10:1758835918774337
pubmed: 29899761
Oncotarget. 2017 Feb 14;8(7):11917-11936
pubmed: 28060758
Biochim Biophys Acta Proteins Proteom. 2019 Dec;1867(12):140203
pubmed: 30822540
Cancer Res. 2011 Sep 15;71(18):5955-60
pubmed: 21896640
Mol Clin Oncol. 2016 Dec;5(6):832-838
pubmed: 28105365
Cancer Res. 2010 Feb 15;70(4):1668-78
pubmed: 20124479
Biomark Med. 2013 Oct;7(5):769-78
pubmed: 24044569
J Transl Med. 2011 Jun 08;9:86
pubmed: 21651777
Cancer Discov. 2014 Nov;4(11):1326-41
pubmed: 25186949
Cancer Discov. 2014 Nov;4(11):1342-53
pubmed: 25223734
Oncotarget. 2017 Aug 4;9(2):1587-1601
pubmed: 29416716
Blood. 1993 Nov 1;82(9):2605-10
pubmed: 8219214
Front Immunol. 2014 Aug 11;5:383
pubmed: 25157254
J Clin Oncol. 1997 Apr;15(4):1553-9
pubmed: 9193352